PEN logo

Penumbra (PEN) Company Overview

Profile

Full Name:

Penumbra, Inc.

Sector:

Healthcare

Country:

United States

IPO:

September 18, 2015

Indexes:

Not included

Description:

Penumbra, Inc. is a medical company focused on innovative treatment methods, which designs, develops, manufactures, and sells medical devices. The company's products are aimed at two main segments: vascular diseases and neurosurgery. In both of these markets, the company offers key products: thrombectomy systems - for removing blood clots (thrombi) and embolization systems - for treating patients with various sizes of aneurysms and other vascular and nervous disorders. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.

Key Details

Price

$261.86

Annual Revenue

$1.06 B(+24.95% YoY)

Annual EPS

$2.32(+4740.00% YoY)

PE Ratio

304.48

Beta

0.55

Events Calendar

Earnings

Next earnings date:

Feb 18, 2025

Recent quarterly earnings:

Oct 30, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 16, 2014

Analyst ratings

Recent major analysts updates

Jan 23, 25 Baird
Outperform
Jan 21, 25 UBS
Buy
Dec 18, 24 Truist Securities
Buy
Dec 17, 24 Oppenheimer
Outperform
Dec 11, 24 Wells Fargo
Overweight
Dec 11, 24 Citigroup
Neutral
Dec 9, 24 Canaccord Genuity
Buy
Dec 2, 24 Morgan Stanley
Equal-Weight
Nov 26, 24 BTIG
Buy
Nov 20, 24 Piper Sandler
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
PEN
prnewswire.comJanuary 21, 2025

ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) has announced that it will hold a conference call to review its financial results for the fourth quarter and the entire year of 2024. This call is scheduled for Tuesday, February 18, 2025, at 4:30 PM Eastern Time, after the market closes.

3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)
PEN
zacks.comJanuary 16, 2025

Penumbra (PEN) is likely to do better than the market because it shows strong growth in its financial performance.

Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?
PEN
zacks.comJanuary 8, 2025

Penumbra (PEN) experienced a significant rise in its share price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to additional price growth in the short term.

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PEN
prnewswire.comDecember 30, 2024

ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) has announced that its management team will be presenting at the 43rd Annual J.P.

Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"
PEN
zacks.comDecember 25, 2024

Penumbra (PEN) has the potential to deliver impressive returns due to its strong growth characteristics.

Here's Why Penumbra (PEN) is a Strong Momentum Stock
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Here's Why Penumbra (PEN) is a Strong Momentum Stock
PEN
zacks.comDecember 18, 2024

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons why you should make use of this tool.

Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
PEN
zacks.comDecember 9, 2024

Penumbra (PEN) is likely to do better than the market because it shows strong growth in its financial performance.

Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?
PEN
zacks.comDecember 3, 2024

PEN remains a focus for investors because of its strong portfolio growth and plans for international expansion.

3 Reasons Growth Investors Will Love Penumbra (PEN)
3 Reasons Growth Investors Will Love Penumbra (PEN)
3 Reasons Growth Investors Will Love Penumbra (PEN)
PEN
zacks.comNovember 21, 2024

Penumbra (PEN) has strong growth characteristics that may allow it to significantly exceed market performance.

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
PEN
prnewswire.comNovember 20, 2024

ALAMEDA, Calif., Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) has announced that its management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024.

FAQ

  • What is the ticker symbol for Penumbra?
  • Does Penumbra pay dividends?
  • What sector is Penumbra in?
  • What industry is Penumbra in?
  • What country is Penumbra based in?
  • When did Penumbra go public?
  • Is Penumbra in the S&P 500?
  • Is Penumbra in the NASDAQ 100?
  • Is Penumbra in the Dow Jones?
  • When was Penumbra's last earnings report?
  • When does Penumbra report earnings?
  • Should I buy Penumbra stock now?

What is the ticker symbol for Penumbra?

The ticker symbol for Penumbra is NYSE:PEN

Does Penumbra pay dividends?

No, Penumbra does not pay dividends

What sector is Penumbra in?

Penumbra is in the Healthcare sector

What industry is Penumbra in?

Penumbra is in the Medical Devices industry

What country is Penumbra based in?

Penumbra is headquartered in United States

When did Penumbra go public?

Penumbra's initial public offering (IPO) was on September 18, 2015

Is Penumbra in the S&P 500?

No, Penumbra is not included in the S&P 500 index

Is Penumbra in the NASDAQ 100?

No, Penumbra is not included in the NASDAQ 100 index

Is Penumbra in the Dow Jones?

No, Penumbra is not included in the Dow Jones index

When was Penumbra's last earnings report?

Penumbra's most recent earnings report was on Oct 30, 2024

When does Penumbra report earnings?

The next expected earnings date for Penumbra is Feb 18, 2025

Should I buy Penumbra stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions